Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited

[cafead]

via Runaway demand for Novo Nordisk A/S’s diabetes and weight-loss drugs has propelled the Danish drugmaker into a class all its own atop Europe’s pharmaceutical sector — and the Stoxx Europe 600 Index — so achieving its 2023 targets should be a shoo-in when it reports next week.

article source